X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (27807) 27807
Publication (2751) 2751
Book Review (593) 593
Newsletter (444) 444
Book / eBook (267) 267
Book Chapter (211) 211
Conference Proceeding (47) 47
Dissertation (27) 27
Magazine Article (13) 13
Data Set (6) 6
Transcript (4) 4
Government Document (3) 3
Newspaper Article (3) 3
Presentation (2) 2
Paper (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (16109) 16109
index medicus (14352) 14352
male (14112) 14112
animals (10774) 10774
stroke (10725) 10725
neurosciences (8652) 8652
female (8630) 8630
clinical neurology (6961) 6961
rats (6257) 6257
middle aged (6103) 6103
aged (5885) 5885
ischemia (5390) 5390
brain (4709) 4709
neurology (4256) 4256
adult (3809) 3809
disease models, animal (3718) 3718
treatment outcome (3716) 3716
risk factors (3494) 3494
cerebral ischemia (3484) 3484
neuroprotection (3158) 3158
brain ischemia - drug therapy (3135) 3135
rats, sprague-dawley (3081) 3081
cerebral infarction (3071) 3071
peripheral vascular disease (2748) 2748
focal cerebral-ischemia (2649) 2649
time factors (2587) 2587
stroke - drug therapy (2568) 2568
mice (2567) 2567
magnetic resonance imaging (2525) 2525
analysis (2484) 2484
pharmacology & pharmacy (2367) 2367
surgery (2334) 2334
care and treatment (2291) 2291
research (2291) 2291
aged, 80 and over (2286) 2286
brain - pathology (2187) 2187
neuroprotective agents - pharmacology (2121) 2121
cerebral-ischemia (2106) 2106
apoptosis (1975) 1975
health aspects (1950) 1950
brain ischemia - pathology (1915) 1915
neuroprotective agents - therapeutic use (1884) 1884
mortality (1859) 1859
inflammation (1850) 1850
infarction (1823) 1823
therapy (1768) 1768
infarction, middle cerebral artery - drug therapy (1724) 1724
oxidative stress (1720) 1720
cerebral infarction - drug therapy (1665) 1665
medicine & public health (1647) 1647
rats, wistar (1640) 1640
neurons (1603) 1603
article (1589) 1589
reperfusion (1566) 1566
retrospective studies (1546) 1546
tomography, x-ray computed (1546) 1546
brain - drug effects (1544) 1544
cerebral blood flow (1529) 1529
cardiovascular diseases (1515) 1515
rodents (1507) 1507
acute ischemic-stroke (1482) 1482
thrombolysis (1367) 1367
ischemic stroke (1362) 1362
medicine (1359) 1359
brain ischemia - physiopathology (1354) 1354
artery occlusion (1338) 1338
patients (1331) 1331
risk (1324) 1324
prognosis (1319) 1319
hypertension (1317) 1317
brain ischemia - metabolism (1313) 1313
drug therapy (1305) 1305
injury (1304) 1304
thrombolytic therapy (1301) 1301
brain - metabolism (1285) 1285
expression (1284) 1284
hemorrhage (1282) 1282
cell biology (1272) 1272
infarction, middle cerebral artery - pathology (1268) 1268
cerebral-artery occlusion (1265) 1265
stroke - pathology (1261) 1261
stroke - etiology (1259) 1259
dose-response relationship, drug (1258) 1258
injuries (1252) 1252
myocardial infarction (1229) 1229
biochemistry & molecular biology (1217) 1217
neurons - drug effects (1207) 1207
diagnosis (1187) 1187
disease (1178) 1178
prevention (1164) 1164
cerebral angiography (1163) 1163
subarachnoid hemorrhage (1163) 1163
brain ischemia - complications (1160) 1160
follow-up studies (1141) 1141
rat (1139) 1139
medical research (1134) 1134
stroke - physiopathology (1133) 1133
intracerebral hemorrhage (1129) 1129
research article (1109) 1109
fibrinolytic agents - therapeutic use (1107) 1107
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (207) 207
UTL at Downsview - May be requested (13) 13
OISE - Stacks (12) 12
UofT at Mississauga - Stacks (12) 12
Holland Bloorview Kids Rehabilitation - Stacks (10) 10
Collection Dvlpm't (Acquisitions) - Closed Orders (9) 9
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
West Park Healthcare Centre - Stacks (5) 5
Online Resources - Online (4) 4
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (3) 3
Baycrest Hospital - Stacks (2) 2
OISE - Lost (2) 2
Robarts - Stacks (2) 2
St. Michael's College (John M. Kelly) - 2nd Floor (2) 2
UofT at Scarborough - Stacks (2) 2
West Park Healthcare Centre - Hospital Department (2) 2
Baycrest Hospital - Wellness Library (1) 1
Credit Valley Hospital - Stacks (1) 1
Gerstein Science - Periodical Stacks (1) 1
Law (Bora Laskin) - Stacks (1) 1
Providence Healthcare - Reference (1) 1
St. Michael's College (John M. Kelly) - 3rd Floor (1) 1
St. Michael's Hospital - Stacks (1) 1
Stacks (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
Trinity College (John W Graham) - Stacks (1) 1
Victoria University Emmanuel College - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (27515) 27515
Japanese (281) 281
German (274) 274
Chinese (182) 182
Spanish (138) 138
French (131) 131
Russian (49) 49
Dutch (21) 21
Norwegian (21) 21
Polish (14) 14
Portuguese (12) 12
Swedish (12) 12
Italian (10) 10
Danish (9) 9
Finnish (7) 7
Hungarian (4) 4
Korean (3) 3
Serbian (3) 3
Icelandic (2) 2
Slovak (2) 2
Bosnian (1) 1
Czech (1) 1
Lithuanian (1) 1
Romanian (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 12, pp. 1119 - 1131
Patients with myocardial infarction and a high-sensitivity CRP level of 2 mg or more per liter were assigned to one of three canakinumab doses or placebo. The... 
C-REACTIVE PROTEIN | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | MYOCARDIAL-INFARCTION | STATIN THERAPY | CLONAL HEMATOPOIESIS | INFLAMMATION | CARDIOVASCULAR-DISEASE | INTERLEUKIN-1-BETA INHIBITION | RISK | CORONARY-ARTERY-DISEASE | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Secondary Prevention | Infection - etiology | Incidence | Dose-Response Relationship, Drug | Anti-Inflammatory Agents - adverse effects | C-Reactive Protein - metabolism | Lipids - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Anti-Inflammatory Agents - administration & dosage | Female | Neutropenia - chemically induced | Interleukin-1beta - antagonists & inhibitors | Stroke - prevention & control | Atherosclerosis - drug therapy | Double-Blind Method | Interleukin-1beta - immunology | Atherosclerosis - blood | Myocardial Infarction - drug therapy | Antibodies, Monoclonal - administration & dosage | Aged | Myocardial Infarction - prevention & control | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | C-reactive protein | Cytokines | Clinical trials | Cardiovascular disease | Innate immunity | Inflammation | Angina | Angina pectoris | Thrombosis | Cholesterol | Disease prevention | Proteins | Arteriosclerosis | Atherosclerosis | Cardiovascular diseases | Health risk assessment | Drug therapy | Drug dosages | Klinisk medicin | Clinical Medicine
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2015, Volume 373, Issue 11, pp. 1021 - 1031
Patients with acute STEMI undergoing PCI were assigned to cyclosporine or placebo. No significant between-group difference was seen in the rate of death,... 
HEART | MEDICINE, GENERAL & INTERNAL | MITOCHONDRIAL PERMEABILITY TRANSITION | PERCUTANEOUS CORONARY INTERVENTION | INJECTION | REPERFUSION INJURY | SIZE | PORE | ISCHEMIA | CARDIOPROTECTION | ASPIRATION | Enzyme Inhibitors - adverse effects | Injections, Intravenous | Double-Blind Method | Humans | Middle Aged | Mortality | Kaplan-Meier Estimate | Male | Combined Modality Therapy | Enzyme Inhibitors - administration & dosage | Cyclophilins - antagonists & inhibitors | Myocardial Infarction - therapy | Myocardial Infarction - drug therapy | Cyclosporine - adverse effects | Cyclosporine - administration & dosage | Electrocardiography | Female | Aged | Heart Failure - epidemiology | Ventricular Remodeling - drug effects | Percutaneous Coronary Intervention | Care and treatment | Usage | Angiography | Heart enlargement | Dosage and administration | Cyclosporine | Heart attack | Occlusion | Myocardial infarction | Heart | Cerebral infarction | Heart attacks | Intravenous administration | Cyclosporins | Angioplasty | Body weight | Coronary artery | Clinical trials | Angina | Patients | Clinical outcomes | Reperfusion | Ventricle | Drug therapy | Heart diseases | Pharmaceuticals | Life Sciences | Bioengineering | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 19, pp. 1791 - 1800
Patients with myocardial infarction 1 to 3 years previously were assigned to ticagrelor, 90 or 60 mg twice daily, or to placebo, in addition to low-dose... 
MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | CLOPIDOGREL | MANAGEMENT | ESC GUIDELINES | AMERICAN-COLLEGE | PREVENTION | ASSOCIATION TASK-FORCE | ACUTE CORONARY SYNDROMES | PRASUGREL | ASPIRIN | Purinergic P2Y Receptor Antagonists - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Risk | Secondary Prevention | Adenosine - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Myocardial Infarction - drug therapy | Adenosine - adverse effects | Adenosine - analogs & derivatives | Intracranial Hemorrhages - chemically induced | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Aged | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Dose-response relationship (Biochemistry) | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Dosage and administration | Ticagrelor | Heart attack | Risk factors | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Heart attacks | Hemorrhage | Long term | Patients | Thrombolysis | Bleeding | Blood platelets | Antagonist drugs | Cardiovascular diseases | Drug therapy | Life Sciences | Human health and pathology
Journal Article